Kazár J, Rehácek J
Institute of Virology, Slovak Academy of Sciences, Bratislava, Czechoslovakia.
Zentralbl Bakteriol Mikrobiol Hyg A. 1987 Nov;267(1):74-8. doi: 10.1016/s0176-6724(87)80190-6.
Of three Q fever vaccine candidates available at present, i.e., phase I corpuscular untreated, soluble, and phase I corpuscular chloroform-methanol treated vaccines, the first two were tested on hundreds of subjects exposed to Q fever. Based on their sufficient immunogenicity (which depends also on the tests employed) and low reactogenicity (providing that subjects with previous contact with Coxiella (C.) burnetii are excluded from vaccination) these two vaccines can be recommended for vaccination of humans at risk. Further studies are required, however, to answer definitively which vaccine type is the most suitable, and facing the problem of C. burnetii strain heterogeneity, to decide whether a monovalent vaccine will be sufficient or a polyvalent vaccine will be necessary.
目前有三种Q热疫苗候选产品，即未经处理的I期微粒疫苗、可溶性疫苗以及经氯仿-甲醇处理的I期微粒疫苗，前两种疫苗在数百名接触过Q热的受试者身上进行了测试。基于其足够的免疫原性（这也取决于所采用的测试方法）和低反应原性（前提是排除既往接触过伯纳特柯克斯体（C. burnetii）的受试者进行疫苗接种），这两种疫苗可推荐用于有风险的人群接种。然而，还需要进一步研究来明确哪种疫苗类型最合适，并且鉴于伯纳特柯克斯体菌株的异质性问题，来决定单价疫苗是否足够或是否需要多价疫苗。
